American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Alkermes plc.

$42.45 -0.82% NASDAQ: ALKS · 15-min delayed

DUBLIN 4,
Public · NASDAQ: ALKS
2,050 employees

Visit website Follow

$7.1BMarket cap

$1.5BRevenue · FY2025

$241.7MNet income

2,050Employees

ALKSNASDAQ

1991IPO

About Alkermes plc.

Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Company facts

Type: Public · NASDAQ: ALKS
Employees: 2,050
IPO date: Jul 16, 1991
Headquarters: CONNAUGHT HOUSE
DUBLIN 4, 00000
Phone: 00-353-1-772-8000
Industry: Pharmaceuticals
Website: Visit site

Registry IDs

Ticker: ALKS Nasdaq
SEC CIK: 1520262
EIN: 981007018
SIC: 2834 PHARMACEUTICAL PREPARATIONS

Is this your company?

This profile is unclaimed — any authorized owner can claim it, control the page, and earn the Verified badge.

Claim this profile

Track American companies

Create a free account to follow Alkermes plc. and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Revenue FY2025: $1.5B
Net income: $241.7M
Total assets: $2.5B
Market cap: $7.1B
Gross margin: 86.7%
Operating margin: 17.2%
Net margin: 16.4%

Source: SEC EDGAR · updated Jun 7, 2026

Multi-year

Revenue & profit trend

FY2021

FY2022

FY2023

FY2024

FY2025

Revenue Net income

FY 2025

Financial statements

Income statement

Revenue: $1.5B
Cost of revenue: $196.5M
Gross profit: $1.3B
Operating expenses: $1.0B
Operating income: $254.0M
Income tax: $49.8M
Net income: $241.7M
EPS (basic): $1.47
EPS (diluted): $1.43

Balance sheet

Total assets: $2.5B
Current assets: $1.9B
Total liabilities: $667.7M
Current liabilities: $543.4M
Shareholders’ equity: $1.8B

Cash flow

Operating cash flow: $520.8M
Investing cash flow: $295.5M
Financing cash flow: $12.4M
Net cash flow: $828.6M

Statements via Polygon.io (SEC filings)

NASDAQ: ALKS

$42.45 -0.82%

15-minute delayed · data by Polygon.io

Past year

$26.13 $43.38

52-week range

Market cap: $7.1B
P/E ratio: 29.7
EPS (diluted): $1.43
Shares outstanding: 168.1M
Open: —
Day range: –
Prev close: —
Volume: —
IPO date: Jul 16, 1991

Market data by Polygon.io · prices are 15-minute delayed

Auto-generated

At a glance

Profitable — net income of $241.7M in FY2025.
Revenue grew 26% from FY2021 to FY2025.
Gross margin of 86.7%, net margin 16.4%.
Trading near its 52-week high.
Valued at a price-to-earnings (P/E) ratio of 29.7.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.